Back to Search Start Over

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

Source :
Business Wire. June 21, 2023
Publication Year :
2023

Abstract

MINNEAPOLIS -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug [...]

Subjects

Subjects :
United States. Food and Drug Administration
Stroke (Disease) -- Care and treatment
Medical research
Medicine, Experimental
Ischemia -- Care and treatment
Clinical trials
Kallikrein
Kidney diseases -- Care and treatment
Business
Business, international

Details

Language :
English
Database :
Gale General OneFile
Journal :
Business Wire
Publication Type :
News
Accession number :
edsgcl.753827524

Tools

Authors Abstract Subjects Details